Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis

Annette Becker; Basant Kumar Thakur; Joshua Mitchell Weiss; Han Sang Kim; Héctor Peinado; David Lyden

doi:10.1016/j.ccell.2016.10.009

Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis

Annette Becker, Basant Kumar Thakur, Joshua Mitchell Weiss, Han Sang Kim, Héctor Peinado, David Lyden

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

1109 Citations (Scopus)

Abstract

Tumor-secreted extracellular vesicles (EVs) are critical mediators of intercellular communication between tumor cells and stromal cells in local and distant microenvironments. Accordingly, EVs play an essential role in both primary tumor growth and metastatic evolution. EVs orchestrate multiple systemic pathophysiological processes, such as coagulation, vascular leakiness, and reprogramming of stromal recipient cells to support pre-metastatic niche formation and subsequent metastasis. Clinically, EVs may be biomarkers and novel therapeutic targets for cancer progression, particularly for predicting and preventing future metastatic development.

Original language	English
Pages (from-to)	836-848
Number of pages	13
Journal	Cancer Cell
Volume	30
Issue number	6
DOIs	https://doi.org/10.1016/j.ccell.2016.10.009
Publication status	Published - 2016 Dec 12

Bibliographical note

Funding Information:
The authors gratefully acknowledge support from the following funding sources: the National Cancer Institute (CA169538 and CA169416 to D.L. and H.P.), the Department of Defense (W81XWH-13-1-0427, W81XWH-13-1-0249, and W81XWH-14-1-0199 to D.L.), the Hartwell Foundation, the Manning Foundation, the Sohn Foundation, the STARR Consortium, the POETIC Consortium, the James Paduano Foundation, The Nancy C. and Daniel P. Paduano Foundation, Alex's Lemonade Stand Foundation, the Champalimaud Foundation, the Children's Cancer and Blood Foundation, the 5th District AHEPA Cancer Research Foundation (all to D.L.), and the Daedalus Fund (Weill Cornell Medicine, to D.L.). H.P. is supported by grants from MINECO (SAF2014-54541-R), ATRES-MEDIA ? AXA, Asociaci?n Espa?ola Contra el C?ncer, WHRI Academy, and Worldwide Cancer Research. B.K.T. was supported by the Jose Carreras Leukemia Foundation (DJCLS R12/06). H.S.K is supported by a Physician-Scientist Program from the Yonsei University College of Medicine. J.M.W. is supported by a Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the NIH (T32GM007739) to the Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program. The content of this study is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Publisher Copyright:
© 2016 Elsevier Inc.

All Science Journal Classification (ASJC) codes

Oncology
Cell Biology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ccell.2016.10.009

Cite this

@article{99658dbd6cb84147bf8814dce57913db,

title = "Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis",

abstract = "Tumor-secreted extracellular vesicles (EVs) are critical mediators of intercellular communication between tumor cells and stromal cells in local and distant microenvironments. Accordingly, EVs play an essential role in both primary tumor growth and metastatic evolution. EVs orchestrate multiple systemic pathophysiological processes, such as coagulation, vascular leakiness, and reprogramming of stromal recipient cells to support pre-metastatic niche formation and subsequent metastasis. Clinically, EVs may be biomarkers and novel therapeutic targets for cancer progression, particularly for predicting and preventing future metastatic development.",

author = "Annette Becker and Thakur, {Basant Kumar} and Weiss, {Joshua Mitchell} and Kim, {Han Sang} and H{\'e}ctor Peinado and David Lyden",

note = "Funding Information: The authors gratefully acknowledge support from the following funding sources: the National Cancer Institute (CA169538 and CA169416 to D.L. and H.P.), the Department of Defense (W81XWH-13-1-0427, W81XWH-13-1-0249, and W81XWH-14-1-0199 to D.L.), the Hartwell Foundation, the Manning Foundation, the Sohn Foundation, the STARR Consortium, the POETIC Consortium, the James Paduano Foundation, The Nancy C. and Daniel P. Paduano Foundation, Alex's Lemonade Stand Foundation, the Champalimaud Foundation, the Children's Cancer and Blood Foundation, the 5th District AHEPA Cancer Research Foundation (all to D.L.), and the Daedalus Fund (Weill Cornell Medicine, to D.L.). H.P. is supported by grants from MINECO (SAF2014-54541-R), ATRES-MEDIA ? AXA, Asociaci?n Espa?ola Contra el C?ncer, WHRI Academy, and Worldwide Cancer Research. B.K.T. was supported by the Jose Carreras Leukemia Foundation (DJCLS R12/06). H.S.K is supported by a Physician-Scientist Program from the Yonsei University College of Medicine. J.M.W. is supported by a Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the NIH (T32GM007739) to the Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program. The content of this study is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = dec,

day = "12",

doi = "10.1016/j.ccell.2016.10.009",

language = "English",

volume = "30",

pages = "836--848",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "6",

}

TY - JOUR

T1 - Extracellular Vesicles in Cancer

T2 - Cell-to-Cell Mediators of Metastasis

AU - Becker, Annette

AU - Thakur, Basant Kumar

AU - Weiss, Joshua Mitchell

AU - Kim, Han Sang

AU - Peinado, Héctor

AU - Lyden, David

N1 - Funding Information: The authors gratefully acknowledge support from the following funding sources: the National Cancer Institute (CA169538 and CA169416 to D.L. and H.P.), the Department of Defense (W81XWH-13-1-0427, W81XWH-13-1-0249, and W81XWH-14-1-0199 to D.L.), the Hartwell Foundation, the Manning Foundation, the Sohn Foundation, the STARR Consortium, the POETIC Consortium, the James Paduano Foundation, The Nancy C. and Daniel P. Paduano Foundation, Alex's Lemonade Stand Foundation, the Champalimaud Foundation, the Children's Cancer and Blood Foundation, the 5th District AHEPA Cancer Research Foundation (all to D.L.), and the Daedalus Fund (Weill Cornell Medicine, to D.L.). H.P. is supported by grants from MINECO (SAF2014-54541-R), ATRES-MEDIA ? AXA, Asociaci?n Espa?ola Contra el C?ncer, WHRI Academy, and Worldwide Cancer Research. B.K.T. was supported by the Jose Carreras Leukemia Foundation (DJCLS R12/06). H.S.K is supported by a Physician-Scientist Program from the Yonsei University College of Medicine. J.M.W. is supported by a Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the NIH (T32GM007739) to the Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program. The content of this study is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Publisher Copyright: © 2016 Elsevier Inc.

PY - 2016/12/12

Y1 - 2016/12/12

N2 - Tumor-secreted extracellular vesicles (EVs) are critical mediators of intercellular communication between tumor cells and stromal cells in local and distant microenvironments. Accordingly, EVs play an essential role in both primary tumor growth and metastatic evolution. EVs orchestrate multiple systemic pathophysiological processes, such as coagulation, vascular leakiness, and reprogramming of stromal recipient cells to support pre-metastatic niche formation and subsequent metastasis. Clinically, EVs may be biomarkers and novel therapeutic targets for cancer progression, particularly for predicting and preventing future metastatic development.

AB - Tumor-secreted extracellular vesicles (EVs) are critical mediators of intercellular communication between tumor cells and stromal cells in local and distant microenvironments. Accordingly, EVs play an essential role in both primary tumor growth and metastatic evolution. EVs orchestrate multiple systemic pathophysiological processes, such as coagulation, vascular leakiness, and reprogramming of stromal recipient cells to support pre-metastatic niche formation and subsequent metastasis. Clinically, EVs may be biomarkers and novel therapeutic targets for cancer progression, particularly for predicting and preventing future metastatic development.

UR - http://www.scopus.com/inward/record.url?scp=85003945007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003945007&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2016.10.009

DO - 10.1016/j.ccell.2016.10.009

M3 - Review article

C2 - 27960084

AN - SCOPUS:85003945007

SN - 1535-6108

VL - 30

SP - 836

EP - 848

JO - Cancer Cell

JF - Cancer Cell

IS - 6

ER -

Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this